cefuroxime has been researched along with Disease Models, Animal in 17 studies
Cefuroxime: Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, GONORRHEA, and HAEMOPHILUS.
cefuroxime : A 3-(carbamoyloxymethyl)cephalosporin compound having a 7-(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido side chain.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The comparative efficacies of amoxicillin and cefuroxime against acute otitis media caused by a penicillin-resistant (MIC, 2 micrograms/ml) Streptococcus pneumoniae strain were assessed in a gerbil model by challenging each ear with 10(7) bacteria through transbullar instillation." | 7.70 | In vivo efficacies of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media. ( Aguilar, L; Cenjor, C; García-Calvo, G; Giménez, MJ; Nieto, E; Parra, A; Ponte, C; Soriano, F, 1998) |
| "Intracameral cefuroxime was found to lower the risk of endophthalmitis after cataract surgery." | 3.78 | Physiological and toxicological effects of cefuroxime on the albino rabbit retina. ( Loewenstein, A; Perlman, I; Shahar, J; Zemel, E, 2012) |
| "The comparative efficacies of amoxicillin and cefuroxime against acute otitis media caused by a penicillin-resistant (MIC, 2 micrograms/ml) Streptococcus pneumoniae strain were assessed in a gerbil model by challenging each ear with 10(7) bacteria through transbullar instillation." | 3.70 | In vivo efficacies of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media. ( Aguilar, L; Cenjor, C; García-Calvo, G; Giménez, MJ; Nieto, E; Parra, A; Ponte, C; Soriano, F, 1998) |
| "The efficacy of amoxicillin/clavulanate and cefuroxime was determined in a gerbil model of otitis media with a mixed Streptococcus pneumoniae plus Haemophilus influenzae middle ear (ME) infection." | 3.70 | Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model. ( Aguilar, L; Cenjor, C; García-Calvo, G; Giménez, MJ; Nieto, E; Parra, A; Ponte, C; Soriano, F, 2000) |
| "Cefuroxime was chosen as the PBP-3-active antibiotic and tobramycin represented the aminoglycosides." | 1.56 | Mode of bacterial killing affects the inflammatory response and associated organ dysfunctions in a porcine E. coli intensive care sepsis model. ( Larsson, A; Lipcsey, M; Maudsdotter, L; Sjölin, J; Skorup, P, 2020) |
| "Cefuroxime was administered in a weight-adjusted dosage equivalent to human medicine (18." | 1.48 | Antibiotic Prophylaxis With Cefuroxime: Influence of Duration on Infection Rate With Staphylococcus aureus in a Contaminated Open Fracture Model. ( Arens, D; Kuehl, R; Metsemakers, WJ; Moriarty, TF; Puetzler, J; Raschke, MJ; Richards, RG; Zeiter, S, 2018) |
| "All animals developed severe sepsis/septic shock." | 1.40 | Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis model. ( Castegren, M; Jonsson, AB; Larsson, A; Lipcsey, M; Maudsdotter, L; Sjölin, J; Skorup, P, 2014) |
| " Using pharmacokinetic parameters of the plasma concentrations in vivo and those of the Hill equation the corresponding time course of ER was calculated and by integration with respect to time (0tERdt), an estimate was obtained of the effect on bacteria." | 1.28 | Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics. ( Brus-Weijer, L; Krul, AM; Mattie, H; van Dokkum, AM; van Strijen, E, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 6 (35.29) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Skorup, P | 3 |
| Maudsdotter, L | 3 |
| Lipcsey, M | 3 |
| Larsson, A | 3 |
| Sjölin, J | 3 |
| Puetzler, J | 1 |
| Metsemakers, WJ | 1 |
| Arens, D | 1 |
| Zeiter, S | 1 |
| Kuehl, R | 1 |
| Raschke, MJ | 1 |
| Richards, RG | 1 |
| Moriarty, TF | 1 |
| Tano, E | 1 |
| Castegren, M | 2 |
| Jonsson, AB | 1 |
| Natividad-Pedreño, M | 1 |
| Nuñez-Chia, A | 1 |
| Cobo-Valenzuela, N | 1 |
| Alcantara-Martos, T | 1 |
| Carrascal, MT | 1 |
| Delgado-Martinez, AD | 1 |
| Shahar, J | 1 |
| Zemel, E | 1 |
| Perlman, I | 1 |
| Loewenstein, A | 1 |
| Stinner, B | 1 |
| Celik, I | 2 |
| Lorenz, W | 1 |
| Dietz, W | 1 |
| Hasse, C | 1 |
| Rothmund, M | 1 |
| Bauhofer, A | 1 |
| Plaul, U | 1 |
| Wulf, H | 1 |
| Torossian, A | 1 |
| García-Alvarez, F | 2 |
| Monzón, M | 2 |
| Grasa, JM | 1 |
| Laclériga, A | 2 |
| Amorena, B | 2 |
| García-Alvarez, I | 1 |
| Navarro-Zorraquino, M | 1 |
| Alvarez, FG | 1 |
| Cenjor, C | 3 |
| Ponte, C | 3 |
| Parra, A | 3 |
| Nieto, E | 3 |
| García-Calvo, G | 3 |
| Giménez, MJ | 4 |
| Aguilar, L | 4 |
| Soriano, F | 3 |
| Barg, N | 1 |
| Hvidberg, H | 1 |
| Struve, C | 1 |
| Krogfelt, KA | 1 |
| Christensen, N | 1 |
| Rasmussen, SN | 1 |
| Frimodt-Møller, N | 1 |
| Pérez-Trallero, E | 1 |
| Alkorta, M | 1 |
| Vicente, D | 1 |
| Gracia, E | 1 |
| Leiva, J | 1 |
| Oteiza, C | 1 |
| Mattie, H | 1 |
| van Dokkum, AM | 1 |
| Brus-Weijer, L | 1 |
| Krul, AM | 1 |
| van Strijen, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU[NCT05511129] | 1,053 participants (Actual) | Observational | 2022-05-12 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
17 other studies available for cefuroxime and Disease Models, Animal
| Article | Year |
|---|---|
Mode of bacterial killing affects the inflammatory response and associated organ dysfunctions in a porcine E. coli intensive care sepsis model.
Topics: Animals; Cefuroxime; Disease Models, Animal; Endotoxins; Escherichia coli; Escherichia coli Infectio | 2020 |
Antibiotic Prophylaxis With Cefuroxime: Influence of Duration on Infection Rate With Staphylococcus aureus in a Contaminated Open Fracture Model.
Topics: Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Bone Plates; Cefuroxime; Disease Models, Ani | 2018 |
Dynamics of Endotoxin, Inflammatory Variables, and Organ Dysfunction After Treatment With Antibiotics in an Escherichia coli Porcine Intensive Care Sepsis Model.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Disease Models, Animal; Drug Therapy, Combination; Endot | 2018 |
Beneficial antimicrobial effect of the addition of an aminoglycoside to a β-lactam antibiotic in an E. coli porcine intensive care severe sepsis model.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Bacterial Load; Cefuroxime; Critical Care; Disease Model | 2014 |
Effect of cefazolin and cefuroxime on fracture healing in rats.
Topics: Animals; Anti-Infective Agents; Cefazolin; Cefuroxime; Contraindications; Disease Models, Animal; Fe | 2016 |
Physiological and toxicological effects of cefuroxime on the albino rabbit retina.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Disease Models, Animal; Dose-Response Relationship, Drug | 2012 |
[Effect of perioperative antibiotic prophylaxis on hemodynamic stability during surgery: detection of complex interaction in a simulated clinical randomized animal study].
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; Antibiotic Prophylaxis; Blood Loss, Surgical | 1998 |
Effects of G-CSF and antibiotic prophylaxis in a 2 x 2 factorial design on outcome in septic rats.
Topics: Abdomen; Animals; Antibiotic Prophylaxis; Cefuroxime; Clinical Trials as Topic; Disease Models, Anim | 2004 |
Interleukin-1, interleukin-6, and interleukin-10 responses after antibiotic treatment in experimental chronic Staphylococcus aureus osteomyelitis.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Cefuroxime; Chronic Disease; Ciprofloxacin; Disease Models | 2006 |
In vivo efficacies of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media.
Topics: Acute Disease; Amoxicillin; Animals; Cefuroxime; Disease Models, Animal; Drug Therapy, Combination; | 1998 |
Comparison of four antibiotics in a murine model of necrotizing cutaneous infections caused by toxigenic Streptococcus pyogenes and Staphylococcus aureus.
Topics: Analysis of Variance; Animals; Anti-Bacterial Agents; Azithromycin; Cefuroxime; Clarithromycin; Dise | 1998 |
Antimicrobial treatment of an experimental otitis media caused by a beta-lactamase positive isolate of Haemophilus influenzae.
Topics: Amoxicillin-Potassium Clavulanate Combination; Animals; beta-Lactamases; Cefuroxime; Cephalosporins; | 1999 |
Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies.
Topics: Animals; Anti-Bacterial Agents; Cefuroxime; Disease Models, Animal; Dose-Response Relationship, Drug | 2000 |
Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model.
Topics: Acute Disease; Amoxicillin-Potassium Clavulanate Combination; Animals; Cefuroxime; Cephalosporins; C | 2000 |
Prediction of in-vivo efficacy by in-vitro early bactericidal activity with oral beta-lactams, in a dose-ranging immunocompetent mouse sepsis model, using strains of Streptococcus pneumoniae with decreasing susceptibilities to penicillin.
Topics: Amoxicillin; Animals; Area Under Curve; Cefpodoxime; Ceftizoxime; Cefuroxime; Cephalosporins; Diseas | 2001 |
A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Biofilms; Cefuroxime; Cephalosporins; Chronic | 2001 |
Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics.
Topics: Agranulocytosis; Animals; Cefamandole; Ceftazidime; Ceftriaxone; Cefuroxime; Cephalosporins; Disease | 1990 |